Mindray Receives FDA Approval for Two Products Targeting North American Market
14 Giugno 2007 - 3:19PM
PR Newswire (US)
SHENZHEN, China, June 14 /Xinhua-PRNewswire-FirstCall/ -- Mindray
Medical International Limited (NYSE:MR), a leading developer,
manufacturer and marketer of medical devices in China with a
rapidly growing international presence, today announced that it has
received 510(k) clearance from the U.S. Food and Drug
Administration (FDA) for its BC-3200, an automatic three-part
differential hematology analyzer, and Hypervisor VI, a central
monitoring system. "We are optimistic about the international
growth potential of these two FDA approved products," said Mr. Xu
Hang, Mindray's Chairman and Co-Chief Executive Officer. "Patients
and hospitals are closely focused on healthcare costs and as a
result we believe that our high-quality and competitively priced
products have a strong competitive advantage in the North American
market." The BC-3200 three-part differential hematology analyzer is
the first automatic diagnostic laboratory instrument introduced by
Mindray targeting the North American market. The BC-3200 is
designed to provide reliable, efficient, and safe closed-tube
sampling with a throughput rate of up to 60 samples per hour. The
device is specifically targeted for cost-sensitive healthcare
facilities and small laboratories as it delivers both more accurate
test results and better overall performance than comparably priced
devices. The Company plans to launch additional diagnostic
laboratory instruments such as biochemistry analyzers and a
five-part differential automatic hematology analyzer in the North
American market in the next 12 to 18 months. The Hypervisor VI
central monitoring system allows hospitals to benefit from powerful
networking and patient data review capabilities. The system can
connect up to 32 bedside patient monitors and allows healthcare
professionals to view and manage data from each connected monitor
and the hospital's record system at a central monitoring station.
The introduction of the Hypervisor VI in the North American market
increases the functionality of three of Mindray's existing patient
monitoring devices including the VS-800, PM-8000 Express and
PM-9000 Express, which are all compatible with the Hypervisor VI
and currently available for sale in the U.S. market. To date,
Mindray has received 510(k) clearance from the FDA for a total of
10 products, covering patient monitoring devices, diagnostic
laboratory instruments, and ultrasound imaging systems. The Company
expects to begin shipment of the BC-3200 to North America in late
June 2007. About Mindray Mindray Medical International Limited is a
leading developer, manufacturer and marketer of medical devices in
China with a significant and growing presence worldwide.
Established in 1991, Mindray offers a broad range of products
across three primary business segments: patient monitoring devices,
diagnostic laboratory instruments, and ultrasound imaging systems.
Mindray is headquartered in Shenzhen, China, and has 29 local sales
and services offices in China, as well as sales and services
offices in Boston, Istanbul, London, Mumbai, Seattle and Vancouver.
For more information, please visit http://www.mindray.com/ . Safe
Harbor Statement This announcement contains forward-looking
statements. These statements are made under the "safe harbor"
provisions of the U.S. Private Securities Litigation Reform Act of
1995. These forward-looking statements can be identified by
terminology such as "will," "expects," "anticipates," "future,"
"intends," "plans," "believes," "estimates" and similar statements.
Statements that are not historical facts, including statements
about Mindray's beliefs and expectations, are forward-looking
statements. Forward-looking statements involve inherent risks and
uncertainties. Information regarding these risks and uncertainties
is included in our public filings with the Securities and Exchange
Commission. All information provided in this press release is as of
June 14, 2007, and Mindray undertakes no duty to update such
information, except as required under applicable law. For investor
and media inquiries please contact: In China: Investor Relations
Mindray Medical International Limited Tel: +86-755-2658-2518 Email:
Justin Knapp Ogilvy Public Relations Worldwide, Beijing Tel:
+86-10-8520-6556 Email: In the United States: Jeremy Bridgman
Ogilvy Public Relations Worldwide, New York Tel: +1-212-880-5363
DATASOURCE: Mindray Medical International Limited CONTACT: In
China, Investor Relations of Mindray Medical International Limited,
+86-755-2658-2518, or ; Justin Knapp of Ogilvy Public Relations
Worldwide, Beijing for Mindray, +86-10-8520-6556, or , or in U.S.,
Jeremy Bridgman of Ogilvy Public Relations Worldwide, New York for
Mindray, +1-212-880-5363 Web site: http://www.mindray.com/
Copyright
Grafico Azioni Montage Resources (NYSE:MR)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Montage Resources (NYSE:MR)
Storico
Da Set 2023 a Set 2024